Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database [0.03%]
基于美国大型商业索赔数据库的直接口服抗凝药阿哌沙班与华法林治疗静脉血栓栓塞患者的临床及经济性比较研究
Jennifer D Guo,Jigar Rajpura,Patrick Hlavacek et al.
Jennifer D Guo et al.
Background: Venous thromboembolism (VTE), constituting deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common cause of vascular-related morbidity and mortality, resulting in a significant clinical and economi...
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A [0.03%]
A型血友病人的emicizumab预防治疗短期和长期结局模型研究
Zheng-Yi Zhou,Karina Raimundo,Anisha M Patel et al.
Zheng-Yi Zhou et al.
Background: Hemophilia A (HA) can result in bleeding events because of low or absent clotting factor VIII (FVIII). Prophylactic treatment for severe HA includes replacement FVIII infusions and emicizumab, a bispecific fac...
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population [0.03%]
口服抗凝药预防非瓣膜性房颤住院和医疗费用的观察研究：美国退伍军人事务局人群分析
Alpesh Amin,Allison Keshishian,Jeffrey Trocio et al.
Alpesh Amin et al.
This article has been corrected. Please see J Manag Care Spec Pharm, 2020;26(5):682 BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs)-including dabigatran, rivaroxaban, apixaban, and edoxaban-are at least as eff...
Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers [0.03%]
伴用CYP3A诱导剂和抑制剂处方oxicodone或oxymorphone的情况分析
D Tyler Coyle,Tiffany S Woodworth,David Moeny et al.
D Tyler Coyle et al.
Background: Oxymorphone's metabolism does not involve the hepatic cytochrome P450 (CYP) system. The effect of this pharmacokinetic feature of oxymorphone on opioid prescribing is unknown. ...
Joyce Hsu
Joyce Hsu
No outside funding supported the writing of this commentary. Hsu reports research support from Vedanta Biosciences and consulting fees from EBSCO, outside the submitted work.
Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications [0.03%]
新诊断为2型糖尿病并开始使用钠葡萄糖共转运蛋白2抑制剂、胰高血糖素样肽1受体激动剂和其他抗糖尿病药物患者的心血管结局
Elmor D Pineda,I-Chia Liao,Paul J Godley et al.
Elmor D Pineda et al.
Background: Cardiovascular disease (CVD) remains the most prevalent cause of morbidity and mortality in patients with type 2 diabetes (T2D) and is a primary driver for health care costs associated with diabetes management...
Effect of Pharmacist-Driven Professional Continuous Glucose Monitoring in Adults with Uncontrolled Diabetes [0.03%]
药师驱动的动态血糖监测在成人难治性糖尿病中的应用效果分析
Christina H Sherrill,Christopher T Houpt,Elisabeth M Dixon et al.
Christina H Sherrill et al.
Background: Diabetes requires close monitoring to achieve optimal outcomes and avoid adverse effects. Continuous glucose monitoring (CGM) is one approach to measuring glycemia and has become more widespread with recent ad...
Katherine Eban
Katherine Eban
No funding was provided for the writing of this article. The author has nothing to disclose.
James T Kenney
James T Kenney
No funding supported the writing of this reflection. The author has nothing to disclose.
Underestimating the Value of an Intervention: The Case for Including Productivity in Value Assessments and Formulary Design [0.03%]
低估了干预措施的价值：在价值评估和药品报销目录设计中纳入生产率的案例分析
Taruja Karmarkar,Jennifer S Graff,Kimberly Westrich
Taruja Karmarkar
Background: Value assessment reports are increasingly being considered in health care coverage decisions. The inputs included and analytic methodologies underlying these reports should include all components of value. ...